Abstract
Monoclonal antibody-based therapy has the theoretic appeal of selective targeting of tumor cells. Most promising is the use of toxins and radioisotope immunoconjugates in the treatment of hematologic malignancies. Obstacles to effective treatment have been defined and solutions are being pursued. The future use of this therapeutic strategy will be determined by creative approaches to enhance delivery, decrease immunogenicity, and maximize potency of antibody reagents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 622-626 |
| Number of pages | 5 |
| Journal | Current opinion in oncology |
| Volume | 6 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1994 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
